MediciNova, Inc. - Common Stock (NQ:MNOV)

1.340 -0.010 (-0.74%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 20, 2026 Add to My Watchlist

Price and Volume

Volume	29,230
Open	1.350
Bid (Size)	1.300 (1,000)
Ask (Size)	1.370 (700)
Prev. Close	1.350
Today's Range	1.330 - 1.360
52wk Range	1.168 - 1.960
Shares Outstanding	49,046,246
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

July 15, 2026

From MediciNova, Inc.

Via GlobeNewswire

MediciNova CEO Provides Shareholder Update

June 30, 2026

From MediciNova, Inc.

Via GlobeNewswire

Performance

YTD	+0.8%	+0.8%
1 Month	+3.1%	+3.1%
3 Month	-8.8%	-8.8%
6 Month	-20.2%	-20.2%
1 Year	+6.3%	+6.3%

More News

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

June 08, 2026

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

May 26, 2026

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ ↗

October 30, 2025

Via Stocktwits

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

April 27, 2026

From MediciNova, Inc.

Via GlobeNewswire

MediciNova to Participate at the 38th Annual ROTH Conference

March 16, 2026

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

January 29, 2026

From MediciNova, Inc.

Via GlobeNewswire

2026 New Year’s Greetings from the CEO

January 06, 2026

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

December 18, 2025

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

December 08, 2025

From MediciNova, Inc.

Via GlobeNewswire

Message from the CEO to MediciNova Shareholders

December 01, 2025

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

November 18, 2025

From MediciNova, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 07, 2025

Via Benzinga

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

November 06, 2025

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

November 04, 2025

From MediciNova, Inc.

Via GlobeNewswire

Unusual volume stocks in Monday's session ↗

November 03, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 31, 2025

Via Benzinga

Which stocks are experiencing notable movement on Friday? ↗

October 31, 2025

Via Chartmill

These stocks have an unusual volume in today's session ↗

October 31, 2025

Via Chartmill

Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗

October 31, 2025

Via Benzinga

Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading? ↗

October 30, 2025

Via Benzinga

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

October 30, 2025

From MediciNova, Inc.

Via GlobeNewswire

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

October 06, 2025

From MediciNova, Inc.

Via GlobeNewswire

MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

September 22, 2025

From MediciNova, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is MediciNova, Inc. - Common Stock publicly traded?

Yes, MediciNova, Inc. - Common Stock is publicly traded.

What exchange does MediciNova, Inc. - Common Stock trade on?

MediciNova, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for MediciNova, Inc. - Common Stock?

The ticker symbol for MediciNova, Inc. - Common Stock is MNOV on the Nasdaq Stock Market

What is the current price of MediciNova, Inc. - Common Stock?

The current price of MediciNova, Inc. - Common Stock is 1.340

When was MediciNova, Inc. - Common Stock last traded?

The last trade of MediciNova, Inc. - Common Stock was at 07/20/26 04:00 PM ET

What is the market capitalization of MediciNova, Inc. - Common Stock?

The market capitalization of MediciNova, Inc. - Common Stock is 65.72M

How many shares of MediciNova, Inc. - Common Stock are outstanding?

MediciNova, Inc. - Common Stock has 66M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.